NCT06257381Completed
Maximal Oxygen Uptake (VO2max) in Patients With COPD
Maximal Oxygen Uptake (VO2max) in Patients With COPD: a Test-Retest Reliability Study
Source: ClinicalTrials.gov · Last updated 9 Jul 2024
Brief summary (registry, in English)
Patients with chronic obstructive pulmonary disease (COPD), facing a decline in lung function and compromised quality of life, often benefit from regular exercise (1). Assessing their cardiorespiratory fitness through maximal oxygen uptake (VO2max) is crucial (2), yet research on its validity and reliability in COPD patients remains sparse. This study aims to fill this gap, examining the content validity and test-retest reliability of the VO2-max test in COPD, comparing it with healthy controls.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 24 (actual)
- First submitted
- 5 Feb 2024
- Start date
- 5 Feb 2024
- Primary completion date
- 8 Jul 2024
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- COPD
- NCT number
- NCT06257381
What you commit to
- Study type: Observational
- Participants enrolled: 24
- From 5 Feb 2024 to the primary completion date, 8 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Symptoms of disease within 2 weeks prior to the study
- Symptoms of disease within 2 weeks prior to the study
Other illness
- Symptoms of ischaemic heart disease
- Known heart failure
- Known malignant disease
- Unstable cardiac arrhythmic disease
- Known chronic lung disease
- Known ischaemic heart disease
- Known heart failure
- Known malignant disease
- Unstable cardiac arrhythmic disease
Other
- Claudication
- Participation in pulmonary rehabilitation within 6 months
- Pregnancy
- Renal or liver dysfunction
- Claudication
- Pregnancy
- Renal or liver dysfunction
Who the study is looking for
- Men and women
- 45-80 years
- COPD (GOLD stage I to IIII)
- Forced expiratory volume in 1 sec (FEV1)/forced vital capacity ratio (FVC) \< 0.8, FEV1 \< 90% of predicted value.
- Modified Medical Research Council score (mMRC 0 - 3)
- Resting arterial oxygenation \> 90%
- Men and women
- 45-80 years
- Normal FEV1, FVC, FEV1/FVC, and single-breath diffusion capacity
- Same sex, age (± 3 years) as the COPD patients
Age in the registry: 40 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark. Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.